CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration
Authors:
- Pawel StockiPSPawel Stocki
- Jaroslaw SzaryJSJaroslaw Szary
- Mykhaylo DemydchukMDMykhaylo Demydchuk
- Leandra NorthallLNLeandra Northall
- Charlotte L. M. RasmussenCRCharlotte L. M. Rasmussen
- Diana Bahu LoganDLDiana Bahu Logan
- Aziz GauharAGAziz Gauhar
- Laura TheiLTLaura Thei
- Shu-Fen CokerSCShu-Fen Coker
- Torben MoosTMTorben Moos
- Frank S. WalshFWFrank S. Walsh
- J. Lynn RutkowskiJRJ. Lynn Rutkowski
Open Access
- 23 February 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 739
Abstract
Since the delivery of biologic drugs to the brain is greatly hampered by the existence of the blood–brain barrier (BBB), brain shuttles are being developed to enhance therapeutic efficacy. As we have previously shown, efficient and selective brain delivery was achieved with TXB2, a cross-species reactive, anti-TfR1 VNAR antibody. To further explore the limits of brain penetration, we conducted restricted randomization of the CDR3 loop, followed by phage display to identify improved TXB2 variants. The variants were screened for brain penetration in mice using a 25 nmol/kg (1.875 mg/kg) dose and a single 18 h timepoint. A higher kinetic association rate to TfR1 correlated with improved brain penetration in vivo. The most potent variant, TXB4, showed a 3.6-fold improvement over TXB2, which had on average 14-fold higher brain levels when compared to an isotype control. Like TXB2, TXB4 retained brain specificity with parenchymal penetration and no accumulation in other organs. When fused with a neurotensin (NT) payload, it led to a rapid drop in body temperature upon transport across the BBB. We also showed that fusion of TXB4 to four therapeutic antibodies (anti-CD20, anti-EGFRvIII, anti-PD-L1 and anti-BACE1) improved their brain exposure between 14- to 30-fold. In summary, we enhanced the potency of parental TXB2 brain shuttle and gained a critical mechanistic understanding of brain delivery mediated by the VNAR anti-TfR1 antibody.Keywords
Funding Information
- Lundbeck Foundation (R155-2013-14113)
This publication has 29 references indexed in Scilit:
- Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal AntibodyCancer Immunology Research, 2015
- AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing GlioblastomaMolecular Cancer Therapeutics, 2015
- Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive propertiesJournal of Clinical Investigation, 2014
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular ShuttleNeuron, 2014
- Dual Host-Virus Arms Races Shape an Essential Housekeeping ProteinPLOS Biology, 2013
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis TargetScience Translational Medicine, 2011
- The role of neurotensin in physiologic and pathologic processesCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunityMedical Microbiology and Immunology, 2009
- Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouseBiotechnology and Bioengineering, 2008
- Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with LysozymeScience, 2004